NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Faeth Therapeutics
ProDa BioTech, LLC
BeiGene
Trishula Therapeutics, Inc.
Arcus Biosciences, Inc.
Sumitomo Pharma America, Inc.
EpiAxis Therapeutics